Novo Nordisk announces new SVP

PRINCETON, N.J. — Global healthcare company Novo Nordisk announced the promotion of Eddie Williams to SVP biopharmaceuticals, effective Feb. 1, 2014.



"Our biopharmaceutical business will be increasingly important to our growth in the U.S. as we apply the protein expertise developed through our diabetes franchise to helping people with hemophilia and growth disorders manage their conditions more effectively," Jesper Hoiland, president of Novo Nordisk, the company's U.S. affiliate, said. "That business has flourished under Eddie's experienced leadership. His promotion to senior vice president demonstrates the company's focus on, and commitment to, our pipeline of life-changing biological therapies."



Williams joined Novo Nordisk in 2006 and currently serves as corporate VP biopharmaceuticals, a role in which he leads the sales and marketing, business development and new product commercialization functions for the company's growing U.S. biopharmaceuticals business.